The Bulletin
The Times


.

Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

  • Written by PR Newswire

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement

AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive...

hacklink esim balkanzlibraryzlibrarySahabet girişuk casinos not on gamstopGamStopgrandpashabet girişjojobetviagra 100 mg fiyat